ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 24251
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 24251

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER (CO45042)

 

Disease Types: Lung Cancer Research

Eligibility Requirements:

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
Measurable disease, as defined by RECIST v1.1
No prior systemic treatment for advanced or metastatic NSCLC
Documentation of the presence of a KRAS G12C mutation
Documentation of known PD-L1 expression status in tumor tissue
Availability of a representative tumor specimen
Adequate end-organ function
Eligible to receive a platinum-based chemotherapy regimen

For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates